CA3124319C - Combination treatment for solid tumors using docetaxel and a cyp3a inhibitor - Google Patents

Combination treatment for solid tumors using docetaxel and a cyp3a inhibitor Download PDF

Info

Publication number
CA3124319C
CA3124319C CA3124319A CA3124319A CA3124319C CA 3124319 C CA3124319 C CA 3124319C CA 3124319 A CA3124319 A CA 3124319A CA 3124319 A CA3124319 A CA 3124319A CA 3124319 C CA3124319 C CA 3124319C
Authority
CA
Canada
Prior art keywords
docetaxel
cyp3a inhibitor
administration
cyp3a
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3124319A
Other languages
English (en)
French (fr)
Other versions
CA3124319A1 (en
Inventor
Jacob Hendrik Beijnen
Johannes Henricus Matthias Schellens
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Modra Pharmaceuticals BV
Original Assignee
Modra Pharmaceuticals BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Modra Pharmaceuticals BV filed Critical Modra Pharmaceuticals BV
Publication of CA3124319A1 publication Critical patent/CA3124319A1/en
Application granted granted Critical
Publication of CA3124319C publication Critical patent/CA3124319C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3124319A 2018-12-21 2019-12-18 Combination treatment for solid tumors using docetaxel and a cyp3a inhibitor Active CA3124319C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18215488.0 2018-12-21
EP18215488 2018-12-21
PCT/EP2019/086125 WO2020127607A1 (en) 2018-12-21 2019-12-18 Combination treatment for solid tumors using docetaxel and a cyp3a inhibitor

Publications (2)

Publication Number Publication Date
CA3124319A1 CA3124319A1 (en) 2020-06-25
CA3124319C true CA3124319C (en) 2023-07-04

Family

ID=64901398

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3124319A Active CA3124319C (en) 2018-12-21 2019-12-18 Combination treatment for solid tumors using docetaxel and a cyp3a inhibitor

Country Status (13)

Country Link
US (1) US20220071944A1 (https=)
EP (1) EP3897611A1 (https=)
JP (3) JP2022514960A (https=)
KR (1) KR20220004011A (https=)
CN (1) CN113473982A (https=)
AU (2) AU2019410062A1 (https=)
BR (1) BR112021012266A2 (https=)
CA (1) CA3124319C (https=)
CL (1) CL2021001635A1 (https=)
IL (1) IL284225A (https=)
MX (1) MX2021007480A (https=)
PE (1) PE20220129A1 (https=)
WO (1) WO2020127607A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20220250A1 (es) * 2018-12-21 2022-02-16 Modra Pharmaceuticals B V Uso de docetaxel en el tratamiento de cancer mediante control de niveles maximos en plasma
GB202201935D0 (en) 2022-02-14 2022-03-30 Modra Pharmaceuticals B V Methods and compositions for treating cancer in taxane-resistant patients
CN116270617B (zh) * 2023-03-29 2024-01-26 济宁医学院附属医院 Arp2/3复合物抑制剂CK-666和多西他赛组合用于癌症治疗的制药用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9089544B2 (en) * 2007-08-24 2015-07-28 Slotervaart Participaties Bv Composition
GB0716591D0 (en) * 2007-08-24 2007-10-03 Vereniging Het Nl Kanker I Composition
MX2010002179A (es) * 2007-08-24 2010-04-27 Stichting Het Nl Kanker I Composicion para el tratamiento de enfermedades neoplasicas.
JP2012500788A (ja) 2008-08-22 2012-01-12 スティヒティング ヘット ネーデルランド カンケル インスティテュート 組成物
PE20220250A1 (es) * 2018-12-21 2022-02-16 Modra Pharmaceuticals B V Uso de docetaxel en el tratamiento de cancer mediante control de niveles maximos en plasma

Also Published As

Publication number Publication date
JP2025094186A (ja) 2025-06-24
JP2023102786A (ja) 2023-07-25
IL284225A (en) 2021-08-31
BR112021012266A2 (pt) 2021-08-31
JP2022514960A (ja) 2022-02-16
EP3897611A1 (en) 2021-10-27
MX2021007480A (es) 2021-10-13
CL2021001635A1 (es) 2022-04-22
CA3124319A1 (en) 2020-06-25
KR20220004011A (ko) 2022-01-11
WO2020127607A1 (en) 2020-06-25
CN113473982A (zh) 2021-10-01
AU2023204693A1 (en) 2023-08-10
AU2019410062A1 (en) 2021-08-12
PE20220129A1 (es) 2022-01-27
US20220071944A1 (en) 2022-03-10

Similar Documents

Publication Publication Date Title
US20250312305A1 (en) Cancer Treatment Using Docetaxel by Controlling Peak Plasma Levels
AU2023204693A1 (en) Combination treatment for solid tumors using docetaxel and a cyp3a inhibitor
EP2638395A1 (en) Methods of treating cancer
US12233072B2 (en) Compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds for treating Adenoid Cystic Carcinoma
US20260027117A1 (en) Methods of treating small cell lung cancer
US20220241294A1 (en) Bisfluoroalkyl-1,4-benzodiazepinone compounds for treating notch-activated breast cancer
EP4385507A1 (en) Combination treatment for solid tumors using cabazitaxel and a cyp3a inhibitor
HK40111479A (en) Combination treatment for solid tumors using cabazitaxel and a cyp3a inhibitor
US20250144083A1 (en) Methods and compositions for treating cancer in taxane-resistant patients
WO2024133947A1 (en) Lurbinectedin and cyp3a4 inhibitor combination
CN101528705A (zh) 17-aag或17-ag或两者之一的前药与her2抑制剂联用治疗乳腺癌的方法

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210618

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 5TH ANNIV.) - SMALL

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241209

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241209

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 6TH ANNIV.) - SMALL

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251125

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251125